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Abstract: MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis.
Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have
been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14
skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies
with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations
responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this
report, we examine three different methodologies to detect METex14 and assess their potential utility
for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution
in NSCLC.
Keywords: Met exon 14 skipping; diagnostic assay; PCR; next generation sequencing; RNA hybridisation
1. Introduction
Non-small cell lung cancer (NSCLC) is a heterogeneous histological and molecular entity.
The discovery of actionable mutations present within a subset of these tumours, most notably mutations
in Epidermal Growth Factor Receptor (EGFR), and rearrangements of anaplastic lymphoma kinase
(ALK) and V-Ros avian UR2 sarcoma virus oncogene homolog 1 (ROS1), has led to the development of
a number of effective targeted treatment options for patients with advanced disease [1].
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MET protooncogene (MET) also known as Hepatocyte Growth Factor Receptor (HGFR) codes for a
receptor tyrosine kinase (RTK) that plays a role in tissue remodelling and morphogenesis. Its only known
ligand is hepatocyte growth factor/scatter factor (HGF/SF), whose binding results in physiological
activation of MET [2]. Its activation results in downstream induction of the Phosphatidylinositol
3-kinase/mechanistic target of rapamycin (PIK3/mTOR), signal transducers and activators of a
transcription (STAT) and Mitogen-activated protein kinase (MAPK) pathways. Abnormal activation
of MET results in increased cell survival, cell proliferation, epithelial–mesenchymal transition (EMT),
invasion and angioinvasion and ultimately, the promotion of oncogenesis. Alterations of MET, such as
protein overexpression, gene amplification and mutations in MET gene juxtamembrane and semaphorin
domains have been observed in a variety of cancers and are associated with a poor prognosis in NSCLC.
A splicing mutation involving the loss of exon 14 (called METex14) is a recently described biomarker
that has emerged as a further potential therapeutic target in patients with NSCLC. The presence of
METex14 skipping has been shown to predict whether or not patients may respond to MET inhibitor
therapy [3]. In this regard, patients with METex14 skipping have been found to be sensitive to MET
inhibitors such as crizotinib, whereas MET protein overexpression or gene amplification results in
no durable response to targeted therapy. This may go some way to explaining why trials with MET
inhibitors have proved disappointing [4,5]. The sensitivity of METex14 skipped patients to MET
inhibitors has resulted in several case reports of dramatic responses in the literature [6,7], and various
clinical trials of MET tyrosine kinase inhibitors in METex14 mutated NSCLC are consequently currently
ongoing [4]. METex14 skipping is also associated with varying clinical phenotypes depending on
the histologic subtype of the tumour encountered. For example, Kwon et al., looking at cohorts
of patients with MET-mutated adenocarcinoma (9/102) and pleomorphic carcinoma (9/45), found
that patients with MET-mutated adenocarcinomas were significantly older than those without MET
mutations (p = 0.015) and were twice as likely to be female (male to female ratio: 3:6) and to have never
smoked (ever-to never-smoker ratio: 2:7) [8]. All MET-mutated adenocarcinomas in the study (9/9)
showed acinar predominant histology with associated lepidic patterns. In contrast, among patients
with MET-mutated pleomorphic carcinomas, the male to female and ever- to never-smoker ratios were
8:1 and 7:1, respectively [8].
METex14 alterations have also been identified in 3–4% of non-small cell lung cancers (NSCLC) [9],
most frequently in lung adenocarcinomas but also in squamous cell carcinomas. Specific mutations
resulting in METex14 skipping are responsible for in-frame deletion of the MET juxtamembrane
domain of the MET receptor, which contains the CBL E3-ubiquitin ligase-binding site. This leads
to inhibition of degradation of the MET receptor, prolonging its activity [10]. Interestingly, a high
incidence of METex14 skipping has been reported in sarcomatoid carcinoma of the lung, although
the incidence varies between studies (ranging from 3% up to 31.8% of cases) [11–19]. Sarcomatoid
lung carcinoma is a rare form of lung carcinoma, accounting for approximately 0.3–1.3% of all lung
malignancies. It comprises a group of poorly differentiated NSCLCs that exhibit areas of sarcoma
or sarcoma-like differentiation, and encompasses 5 histologic subgroups—pleomorphic carcinomas,
spindle cell carcinomas, giant cell carcinomas, carcinosarcomas and pulmonary blastomas. Clinically,
it is associated with a poor prognosis and a reduced response to chemotherapeutic agents [20].
From a diagnostic pathology perspective, the identification, where technically possible, of treatment
predictive biomarkers in situ within tumour cells must be highly reproducible, particularly when using
well validated immunohistochemistry [21,22]. Immunohistochemistry has unfortunately not proven
useful thus far for the detection of METex14 splice mutations. MET antibodies are not specific for the
METex14 splice variant mutation; they detect MET overexpression, for which there can be numerous
causes, e.g., increased gene copy number, gene amplification, METex14 skipping, etc. In addition, a
high degree of inter-observer variability has been reported in the scoring of immunohistochemistry
(IHC) slides [5]. Recently, the reproducibility and reliability of RNA in situ hybridisation (RISH)
has significantly advanced with the advent of novel in situ hybridisation techniques, such as the
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BaseScopeTM methodology developed by ACDbio. This technology has been subsequently optimized
for the detection of MET exon 14 skipping [23].
RT-PCR is also a validated and effective method for detecting this particular mutation; however,
it lacks the in situ visualization component of IHC or RISH [4,10].
In this study we aimed to optimize, validate and subsequently compare a variety of laboratory
techniques to reliably detect the presence of METex14 skipping in NSCLC in formalin-fixed
paraffin-embedded (FFPE) tissue.
2. Materials and Methods
2.1. Patient Cohort
Our initial cohort for analysis comprised patients from multiple cancer centres and institutes
with NSCLC (total n = 6, comprising n = 1 (St. James’s Hospital—SJH), n = 2 (St. Vincents University
Hospital—SVUH) and n = 3 St Gallen; Table 1, Cohort 1) whose tumours had been confirmed to
possess METex14 skipping mutations by Next Generation Sequencing (NGS), currently the gold
standard method of detection and for which sufficient tissue remained to assess METex14 skipping
with additional techniques. As METex14 skipping mutations are relatively rare, we elected to enrich
our cohort with patients who had been diagnosed with primary sarcomatoid carcinoma of the lung.
A retrospective search of our laboratory’s pathology database identified a further 20 patients diagnosed
with primary pulmonary sarcomatoid carcinoma who had undergone surgical resection of their tumour
from 2011 to 2017 (Table 1, Cohort 2). FFPE tissue from these patients’ tumours was used to detect the
presence or absence of METex14 skipping.
Table 1. Patient samples used in this study.
Patient Specimens Specimen Type
Modalities Used to
Confirm Presence of
METex14 Skipping
METex14
Skipping
Present
Cohort 1
Patient 1 (SJH01) Lung resection—Adenocarcinoma PCR, RISH, NGS Y
Patient 2 (SVUH001) Lung resection—Adenocarcinoma PCR, RISH, NGS Y
Patient 3 (SVUH002) Lung resection—Sarcomatoid carcinoma PCR, RISH, NGS Y
Patient 4 (SG01) Lymph Node—Large cell lung carcinoma PCR, RISH, NGS Y
Patient 5 (SG02) Lung resection—Adenocarcinoma PCR, RISH, NGS Y
Patient 6 (SG03) Lung resection—Undifferentiated-pleomorphiccancer of the lung PCR, RISH, NGS Y
Cohort 2
001 Lung resection—Sarcomatoid carcinoma PCR N
002 Lung resection—Sarcomatoid carcinoma PCR, RISH, NGS Y
003 Lung resection—Sarcomatoid carcinoma PCR N
004 Lung resection—Sarcomatoid carcinoma PCR N
005 Lung resection—Sarcomatoid carcinoma PCR N
006 Lung resection—Sarcomatoid carcinoma PCR N
007 Lung resection—Sarcomatoid carcinoma PCR N
008 Lung resection—Sarcomatoid carcinoma PCR N
009 Lung resection—Sarcomatoid carcinoma PCR N
010 Lung resection—Sarcomatoid carcinoma PCR N
011 Lung resection—Sarcomatoid carcinoma PCR N
012 Lung resection—Sarcomatoid carcinoma PCR N
013 Lung resection—Sarcomatoid carcinoma PCR N
014 Lung resection—Sarcomatoid carcinoma PCR N
015 Lung resection—Sarcomatoid carcinoma PCR N
016 Lung resection—Sarcomatoid carcinoma PCR N
017 Lung resection—Sarcomatoid carcinoma PCR N
018 Lung resection—Sarcomatoid carcinoma PCR, RISH, NGS Y
019 Lung resection—Sarcomatoid carcinoma PCR N
020 Lung resection—Sarcomatoid carcinoma PCR N
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2.2. Ethics
All patients gave their informed consent for inclusion before they participated in the study. This
study was conducted in accordance with the Declaration of Helsinki. Studies were completed on
FFPE specimens with approval from the relevant Hospital Ethics Committees (SJH/AMNCH—#
041018/8804—approval date 24/10/2004, SVUH Protocol, PIL/Consent vs. 4—approval date 21/04/2009
and St Gallen EKSG 17/013).
2.3. Polymerase Chain Reaction (PCR)
A one-step RT-PCR end-point PCR assay to examine for the detection of METex14 skipped
mRNAs in FFPE was designed, optimized and tested in this enriched cohort of NSCLC patients.
Initial attempts at performing PCR found that standard end-point PCR resulted in a significant rate
of false positive results. However, this issue was resolved with the introduction of one-step RT-PCR
methodology using a Verso 1-Step RT-PCR kit (Thermo Fisher Scientific, Waltham, MA, USA; Cat
No. AB-1454/LD/A). This kit incorporates a Taq DNA polymerase that has reverse transcriptase
activity with high processivity at temperatures of up to 57 ◦C, delivering effective reverse transcription
through difficult RNA secondary structures. Total RNA was isolated from freshly cut 5 µm thick FFPE
sections, or directly from slides using a Qiagen RNeasy ©FFPE kit (Qiagen, Germantown, MD, USA;
Cat No./ID: 73504), and this was quantified with a nanodrop-1000 (Thermo Fisher Scientific, Waltham,
MA, USA). One hundred nanograms was subsequently examined for the presence of Met exon14
skipping using primers spanning exons 13–15 by means of a Verso 1-Step RT-PCR kit (Thermo Fisher
Scientific, Waltham, MA 02451, USA Cat No. AB-1454/LD/A). To assess for the presence of METex14
skipped transcripts, 100 ng of total RNA was subjected to 1-step RT-PCR using the following primers:
METex14 FWD: 5′-TTGGGTTTTTCCTGTGGCTG-3′
METex14 REV: 5′-GGATACTGCACTTGTCGGCA-3′.
To assess for the presence of 18S rRNA, 100 ng of total RNA was subjected to 1-step RT-PCR using
the following primers:
18S rRNA FWD: 5′-GATGGGCGGCGGAAAATAG-3′
18S rRNA REV: 5′-GCGTGGATTCTGCATAATGGT-3′.
The PCR cycling conditions for 1-step RT-PCR were as follows: cDNA synthesis at 50 ◦C for
15 min, followed by Verso Enzyme inactivation at 95 ◦C for 2 min; then, 45 cycles of amplification
with denaturation at 95 ◦C for 20 s, annealing at 60 ◦C for 30 s, extension at 72 ◦C for 60 s and a final
extension step at 72 ◦C for 5 min.
All PCR products were electrophoresed on 2% agarose gel. The PCR products expected using
these primers were as follows; Met WT: 235 bases; METex14: 94 bases; and 18S rRNA: 165 bases.
For each MET specific PCR, a positive wild-type (WT) control (A549) and a positive METex14 control
(NCI-H596) were included, along with negative controls.
The sensitivity of the RT-PCR assay was assessed using GBlocks engineered to exactly mimic
the wildtype and Met exon 14 sequences. For the GBlock sensitivity assay, GBlocks were synthesized
by IDTdna (Integrated DNA Technologies, Inc. Skokie, Illinois 60076, USA), reconstituted to a final
concentration of 10 ng/µL and mixed in the following proportions according to Table 2 to create the
following standard curve.
The PCR protocol was modified to remove the cDNA synthesis step, and the assay was run using
5 ng of diluted GBlock. When diluted with decreasing amounts of METex14, the sensitivity of the
assay using the Verso 1-Step kit is approximately 10%. A similar assay was subsequently conducted
using the same strategy by admixing WT and MetEx14 mutated patient RNA in the same percentages,
and conducting the assay including the cDNA synthesis step. The only modification was that the final
total of RNA in each sample was 100 ng.
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Table 2. GBlock dilution for assay sensitivity testing.
Standard % METex14 METex14 GBlock(10 ng/µL) (µL)
MetWT GBlock
(10 ng/µL) (µL)
Total DNA
(ng)
1 100 5 0 50
2 75 3.75 1.25 50
3 50 2.5 2.5 50
4 25 1.25 3.75 50
5 10 0.5 4.5 50
6 5 0.25 4.75 50
7 0 0 0 50
2.4. Next-Generation Sequencing (NGS)
Cases of sarcomatoid carcinoma which were proven to possess the METex14 splice variant by
RT-PCR were subsequently confirmed to be positive by targeted sequencing of these samples by
NGS. Library preparation was performed according to the Oncomine Focus assay protocol (Thermo
Fisher Scientific, Waltham, MA 02451, USA), starting with 10 ng of DNase-treated RNA. Samples were
multiplexed using IonCode barcode adapters (Thermo Fisher Scientific, Waltham, MA, USA). Final
RNA libraries were quantified by quantitative PCR by using the Ion Library Quantitation Kit (Thermo
Fisher Scientific, Waltham, MA, USA) and then diluted to 100 pM and pooled. Templating reactions
and chip loading were performed using the Ion 510™ & Ion 520™ & Ion 530™ Chef Kit (Thermo Fisher
Scientific, Waltham, MA, USA) and sequenced using 200 bp sequencing with Ion 530™ chips. Sample
de-multiplexing and initial quality controls were performed on the Torrent Suite Server version 5.4
(Thermo Fisher Scientific, Waltham, MA, USA). Demultiplexed data were uploaded to a local Ion
Reporter server for combined DNA and RNA analysis with the Oncomine Focus v2.0 pipeline on Ion
Reporter version 5.0 software both Thermo Fisher Scientific, Waltham, MA, USA).
2.5. RNA In Situ Hybridisation (RISH)
Using a METex14 skipped cell line (NCI-H596), RISH was optimised and performed on full-face
sections of surgically resected tumour from PCR/NGS positive cases using a specific BaseScope™
Assay (Techne/ACDbio, Abingdon, UK). This assay utilises 3 probes in addition to positive and
negative controls tested in parallel. One probe, designed to detect the junction between exons 12
and 13, is considered common and can detect both wild-type MET and METex14 skipped mRNA
(Techne/ACDbio, Abingdon, OX14 3NB, United Kingdon Cat No. 701821). The second probe is
designed to detect the junction between exons 14 and 15 (Techne/ACDbio, Abingdon, OX14 3NB,
United Kingdon Cat No. 701811) and detects only MET mRNA containing exon 14 (wild-type MET).
The third probe is designed to detect the junction between exons 13 and 15 (Techne/ACDbio, Abingdon,
OX14 3NB, United Kingdon Cat No. 701801) and detects only METex14 skipped mRNA. Briefly, 3 µm
sections of FFPE tumour were deparaffinised by submersion in xylene and washed with 100% ethanol.
Target antigen retrieval was performed by incubating the deparaffinised sections at 100 ◦C for 15 min.
Sections were then rinsed in dH2O, dipped in 100% ethanol for 3 min and air dried. A hydrophobic
barrier was applied surrounding the tissue on the slide. Suitable positive and negative controls, in
addition to the relevant probes described above, were added to the deparaffinised tissue sections and
successive amplification steps were performed. A fast red dye was applied to the tissue sections for
signal detection. The slides were subsequently analysed and scored by light microscopy.
3. Results
3.1. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
During the optimization of the RT-PCR assay, it became clear that RNA fragmentation during
FFPE fixation detection of wildtype MET was, for the most part, undetectable, whilst METex14 was
readily detectable due to its smaller amplicon size (Figure 1A). As such, those samples that were
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negative for any amplification product were deemed wildtype MET. However, to ensure that the
lack of amplification was not a consequence of poor RNA quality, we examined a subset of samples
for the expression of 18S rRNA. Amplification was observed in all samples (Figure 1A). Once the
RT-PCR conditions had been optimized, we then tested our assay on a “training cohort” comprising
samples (n = 6) known to be METex14 skipped, and confirmed the specificity of this assay on FFPE
extracted RNA from known METex14 skipped NSCLC cases isolated from three different centres
(Figure 1B).We then tested a “validation cohort” of pulmonary sarcomatoid carcinomas (PSCs) (n = 20)
to test for the presence of METex14 skipping. We identified METex14 skipped mutations in 10% (2/20)
of sarcomatoid patients. The remaining 18 cases (18/20, 90%) were METex14 wildtype (Figure 1C).
These results are in agreement with other studies that investigated the incidence of METex14 skipping
in sarcomatoid carcinoma [15–18].Diagnostics 2018, 8, x FOR PEER REVIEW    7  of  16 
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detecting  WT  MET  in  FFPE  embedded  samples.  A  subset  of  FFPE  samples  were  subsequently 
examined  for  the  expression of  18S  rRNA. Amplification was  observed  across  all  specimens.  (B) 
Confirmation of the specificity of the MetEx14 assay on FFPE extracted RNA from known METex14 
skipped  NSCLC  cases  from  three  hospitals:  St  James’s  Hospital  (SJH);  St  Vincent’s  University 
Hospital  (SVUH)  and  St Gallen  (SG).  (C) Assessment  of  a  cohort  of  20  pulmonary  sarcomatoid 
carcinomas  (PSCs)  for  METex14  skipped  samples.  *  indicates  that  a  given  sample  exhibits  the 
MetEx14 skipping mutation. 
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the  first  instance,  synthesized  DNA  fragments  (Figure  2A).  Our  results  determined  that  the 
sensitivity of this endpoint RT‐PCR could potentially detect METex14 skipped RNA with a  lower 
limit  of detection  of  approximately  10%  (Figure  2A). We  then  tested  the  potential  sensitivity  in 
patient  material  using  the  same  strategy  of  dilution  for  patient  admixed  RNA,  and  the  results 
showed a similar sensitivity of 10% (Figure 2B). This therefore indicates that the PCR methodology 
presented is robust enough to allow for analysis of samples from multiple centres. 
Figure 1. End-point PCR detection of METex14 in three cohorts of non-small cell lung cancer (NSCLC)
formalin-fixed paraffin-embedded (FFPE). (A) Amplification of the Wild-Type amplicon is limited
primarily to high-quality RNA. Samples from snap-frozen tumour tissues versus a sample isolated
from an FFPE embedded specimen show that the integrity/quality of RNA is important for detecting
WT MET in FFPE emb dded amples. A subset of FFPE samples were subsequently examined for the
expression of 18S rRNA. Amplification was observed across all specimens; (B) Co firmation of the
specificity of the MetEx14 assay on FFPE extracted RNA from known METex14 skipped NSCLC cases
from three hospitals: St James’s Hospital (SJH); St Vincent’s University Hospital (SVUH) and St Gallen
(SG); (C) Assessment of a cohort of 20 pulmonary sarcomatoid carcinomas (PSCs) for METex14 skipped
samples. * indicates that a given sample exhibits the MetEx14 skipping mutation.
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We then tested the potential sensitivity of this assay using a dilution of WT/METex14 using, in the
first instance, synthesized DNA fragments (Figure 2A). Our results determined that the sensitivity of
this endpoint RT-PCR could potentially detect METex14 skipped RNA with a lower limit of detection
of approximately 10% (Figure 2A). We then tested the potential sensitivity in patient material using the
same strategy of dilution for patient admixed RNA, and the results showed a similar sensitivity of 10%
(Figure 2B). This therefore indicates that the PCR methodology presented is robust enough to allow for
analysis of samples from multiple centres.Diagnostics 2018, 8, x FOR PEER REVIEW    8  of  16 
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10%. 
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METex14 skipping mutation identified by RNA sequencing by NGS. 
3.3. RNA In Situ Hybridisation (RISH) 
RISH was performed on FFPE sections  taken  from  resection specimens of patients  that were 
confirmed  to harbour a METex14 skipping mutation by RT‐PCR and next‐generation sequencing. 
All tested cases were confirmed as METex14 skipped by RISH, with positive signals detected with 
the probes E13/15 and E12/13, and absence of a detectable signal with the E14/15 probe (Figure 3). 
Figure 2. Assay sensit vity for end-point P f Tex14 skipping. Sensit vity to detect
MetEx14 was measured using eith r (A) GBlocks or (B) admixtures of patient FFPE RNA with limiting
amounts/percentages of WT/METex14 as indicated. The limit of detection was found to be 10%.
3.2. Next-Generation Sequencing (NGS)
Cases that demonstrated METex14 skipping by RT-PCR were confirmed using targeted RNA
sequencing by NGS. All cases demonstrating METex14 skipping by PCR had a corresponding METex14
skipping mutation identified by RNA sequencing by NGS.
3.3. RNA In Situ Hybridisation (RISH)
RISH was performed on FFPE sections taken from resection specimens of patients that were
confirmed to harbour a METex14 skipping mutation by RT-PCR and next-generation sequencing.
All tested cases were confirmed as METex14 skipped by RISH, with positive signals detected with the
probes E13/15 and E12/13, and absence of a detectable signal with the E14/15 probe (Figure 3).
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Figure 3. RISH analysis. Probe design for the detection of METex14 using the ACDbio BaseScope™ 
assay. One probe (blue—(i)), designed to detect the junction between exons 12 and 13, is considered 
common  and  can detect  both wild‐type MET  and METex14 mRNA. A  second  probe  (orange)  is 
designed to detect the junction between exons 14 and 15 (ii) and detects only MET mRNA containing 
exon 14 (wild‐type MET). A third probe is designed to detect the junction between exons 13 and 15 
(iii) and detects only METex14 skipped mRNA (METex14). The three probes are tested in parallel. An 
example of RISH on a patient sample using  these probes demonstrating  the presence of METex14 
skipping. 20× magnification of  (Panel A) exon 12/13 probe  (detects all MET);  (Panel B) exon 14/15 
probe  (detects wild‐type MET);  (Panel C) exon 13/15 probe  (detects  (METex14)).  In  this example, 
almost the entire sample demonstrates METex14. (Panel D) 40× magnification of the (iii) exon 13/15 
probe (METex14), while (Panel E) is a H&E stain from the same sample. 
A summary of the patient samples and the results for each assay is presented in Table1. 
4. Discussion 
The  treatment  of  advanced  stage  NSCLC  has  been  transformed  in  recent  years  by  the 
identification of biomarkers,  such as EGFR  sensitizing  and  resistance mutations, ALK and ROS1 
rearrangements, PD‐L1 expression and tumour mutational burden assessment, allowing clinicians 
to tailor therapy using tyrosine kinase inhibitors and immunotherapeutic and chemotherapy agents 
[1,5,24,25]. Most  recently,  the discovery  that  certain METex14 mutations  are potential drivers  of 
disease  in  NSCLC,  exhibiting  sensitivity  to  treatment  with  MET‐inhibitor  therapy,  has  led  to 
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progression‐free survival have been documented in patients harbouring EGFR mutations and ALK 
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have  demonstrated  disappointing  results  [34–36].  Significantly,  however,  these  trials  targeted 
Figure 3. RISH an lysis. Probe design for th tion of METex14 using the ACDbio BaseScope™
assay. One probe (blue—(i)), designed to detect t j ti n betw en exons 12 and 13, is considered
common and can detect both wild-type MET and METex14 mRNA. A second probe (orange) is designed
to detect the junction between exons 14 and 15 (ii) and detects only MET mRNA containing exon 14
(wild-type MET). A third probe is designed to detect the junction between exons 13 and 15 (iii) and
detects only METex14 skipped mRNA (METex14). The three probes are tested in parallel. An example
of RISH on a patient sample using these probes demonstrating the presence of METex14 skipping. 20×
magnification of (Panel A) exon 12/13 probe (detects all MET); (Panel B) exon 14/15 probe (detects
wild-type MET); (Panel C) exon 13/15 probe (detects (METex14)). In this example, almost the entire
sample demonstrates METex14. (Panel D) 40×magnification of the (iii) exon 13/15 probe (METex14),
while (Panel E) is a H&E stain from the same sample.
A summary of the patient samples and the results for each assay is presented in Table 1.
4. Discussion
The treatment of advanced stage NSCLC has been transformed in recent years by the identification
of biomarkers, such as EGFR s nsitizi g and resistance mutations, ALK and ROS1 rearra gements,
PD-L1 exp ession and tumour mutational urden assessment, allowing clinicians to tailor therapy
using tyrosine kinase inhibitors and immunotherapeutic and chemotherapy agents [1,5,24,25]. Most
recently, the discovery that certain METex14 mutations are potential drivers of disease in NSCLC,
exhibiting sensitivity to treatment with MET-inhibitor therapy, has led to renewed interest in MET as
a targetable biomarker. Accurate, reliable and timely detection of these mutations is paramount in
patients with advanced NSCLC. Meaningful improvements in progression-free survival have been
documented in patients harbouring EGFR mutations and ALK rearrangements [26–28] who have
received tyrosine kinase inhibitor therapy, and case reports and case series have begun to show this
may also be achievable in those patients with METex14 skipping [3,6,7,19,29–33].
Initial phase III clinical trials investigating the effect of MET inhibitors in patients with NSCLC
have demonstrated disappointing results [34–36]. Significantly, however, these trials targeted patients
exhibiting MET overexpression/amplification and did not examine patients with METex14 mutations
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exclusively. However, as mentioned above, several studies have emerged showing clinical responses
in patients with METex14 skipped NSCLC who were treated with MET inhibitors [3,6,7,19,29–32].
Paik and colleagues prospectively identified eight patients with stage IV lung adenocarcinoma who
harboured METex14 splice site alterations [29]. In this study, four patients were treated off-label with
MET-inhibitor therapy (three patients received crizotinib, one patient received cabozantinib). All four
patients experienced either a partial (n = 3) or complete response (n = 1) of their tumours (as defined
as per Response evaluation criteria in solid tumors (RECIST) criteria) to MET inhibitor therapy [29].
A further study by Frampton et al. [3] demonstrated significant clinical responses in one patient treated
with crizotinib (>60% partial response) and in two further patients who were treated with capmatinib
as part of a phase II clinical trial (53% and 61% partial responses, respectively) [3]. After demonstrating
a high rate of occurrence of the METex14 skipping mutation in a cohort of patients with pulmonary
sarcomatoid carcinoma (PSC), Liu et al., described one patient with advanced chemotherapy-refractory
PSC who had a dramatic response to treatment with crizotinib [19]. Heist et al., described a patient
with metastatic squamous cell carcinoma with confirmed METex14 skipping who was treated with
crizotinib. A dramatic treatment response was seen radiologically at 4 weeks, and the response was
maintained for at least 6 months [37]. A number of other case reports have documented similar
responses in patients with advanced stage NSCLC [6,7,30–32].
Robust data on progression-free and overall survival in patients with METex14 skipping treated
with MET inhibitor therapy are however lacking. Randomized controlled trials have yet to be performed
to specifically address this question. However, combining the results of Paik et al. and Frampton et al.,
the reported duration of therapy before progression ranged from approximately 3 months to 13 months
(n = 7 patients) [3,29].
METex14 skipping occurs as a result of exon 14 splice site alterations which demonstrate diverse
genomic sequence compositions. The various alterations comprise base substitutions and indels
(insertion or deletion of bases in the sequence) in exon 14 slice acceptor sites, splice donor sites and
in the −25 bp intronic noncoding region adjacent to the splice acceptor site [3]. Various techniques
have been used successfully to detect the presence of METex14 skipping, including RT-PCR and
next-generation sequencing, as summarized in Table 3.
High MET expression by immunohistochemistry is correlated with METex14 skipping. However,
immunohistochemistry detects MET protein overexpression regardless of the underlying MET
abnormality and does not specifically identify METex14 skipped tumours. The European Thoracic
Oncology Platform (ETOP) found that in a well-defined NSCLC Lungscape cohort of 1572 patients,
both MET amplification and MET gene copy number (GCN) were significantly associated with IHC
MET positivity (p < 0.001) [5]. Importantly, they found neither MET expression nor GCN status,
including amplification and polysomy, were significantly associated with tumour stage and had no
impact on the measured outcome. Another issue observed was high inter-laboratory variability in
MET IHC analysis. The IHC positivity rate varied between 1.6% and 41.6%, and two centres were
found to be significantly over-rating and under-rating respectively [5]. In a further study by Lee et al.,
that evaluated 17 patients with confirmed METex14 skipping, MET immunohistochemistry had a
sensitivity of 100% but a specificity of only 70.4% for detection of the METex14 skipping mutation [38].
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Table 3. Comparison of common modalities used for the detection of METex14 skipping.
Immunohistochemistry PCR RNA In Situ Hybridisation Next-Generation Sequencing
Benefits
-Cheap and cost-effective
-Rapid result
-Easily performed by a standard
pathology laboratory
-Direct visualisation of tissue
-Rapid result
-Reliable, accurate method
of detection
-Direct visualisation of tissue
-Reliable, accurate method
of detection
-High throughput
-Reliable, accurate method of detection
-Ability to multiplex
-Automated analysis
Disadvantages
-Not specific for MET exon 14
skipping splice variant
-Heterogeneity of staining has
been reported
-Interobserver variability
-No direct visualisation of tissue
-Easily performed by a standard
pathology laboratory
-Expensive reagents
-More time consuming if process
not automated
-Requires multiple sections
-High start-up costs
-Dedicated data analysis and
storage required
-No direct visualisation of tissue
-Reduced sensitivity for large insertions
or deletions >20 base pairs (bp)
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RT-PCR is one of the most sensitive techniques currently available for mRNA detection and
quantitation. PCR is an effective technique for METex14 detection, as it can specifically target the
E13/E15 splice region. It is a reliable, efficient and cost-effective laboratory method and can be
performed in a standard histopathology laboratory without the need for specialised equipment.
Some limitations to the use of PCR exist—for instance it has been shown previously to be a less
sensitive and specific technique for the detection of gene fusion products, such as with ALK gene
rearrangement, where the large diversity of break-points in EML4/ALK fusion transcripts makes
PCR challenging, and, in this situation, the use of fluorescent in situ hybridization (FISH) FISH has
proven a superior testing method [24]. However, the METex14 splice variant has been successfully
detected by quantitative reverse transcription PCR in a number of studies [8,17,19]. Another limitation
is that this is an RNA-based assay, and its success relies on the RNA quality in the specimen tested.
Inadequate fixation of tissue or prolonged ischaemia of tissue has the potential to induce a false
negative result. However, the methodology optimized in this study included the analysis of METex14
on RNA isolated from patient formalin-fixed paraffin-embedded (FFPE) specimens suggesting that
this may be a cost-effective and effective rapid screen to test for METex14 skipped patients prior to
confirmation using more expensive assays such as targeted NGS or RISH. Such a strategy was recently
employed by Kim et al., [9], who used real-time quantitative reverse transcription polymerase chain
reaction (qRT-PCR) and Sanger sequencing for their first assessment, followed by next-generation
sequencing (NGS; hybrid-capture targeted DNA/RNA sequencing) [9]. One issue in the development
of an RT-PCR based assay is the quality of the RNA isolated. Our assay currently assumes that if
amplification of MET is negative, then this represents a MET WT sample, but could also indicate
that the RNA integrity may be too poor. As can be seen from Figure 1A, we attempted to test this
by examining amplification of a different target—in this case, 18S rRNA. Amplification of 18S rRNA
was detected in all samples tested, but was non-uniform, suggesting that RNA degradation, as a
consequence of the FFPE process, affects the ability of this type of assay to detect larger PCR products
in FFPE specimens. It may therefore be essential to design primers that (a) have a smaller amplicon
size, and (b) for the purposes of examining WT MET, a second set of primers designed to amplify from
exons 13 and 14, or 14 and 15 and having a similar amplicon size to those for METex14 may prove
useful for screening and ruling out issues of RNA integrity.
NGS is now a well-developed technology with the capability of identifying METex14
skipping [3,15–17,19,39]. A major strength of next-generation sequencing is that it can detect a wide
array of genetic abnormalities including substitutions, deletions, insertions, duplications, copy number
changes, chromosome inversions and chromosome translocations. It can therefore accurately detect
the METex14 splice variant with good sensitivity and specificity. Another advantage is that less
DNA or RNA is required to detect these abnormalities than that required for traditional DNA/RNA
sequencing methods.
Despite the continuous downward trend in the cost of NGS, the expense of this technology can
prove prohibitive to its widespread availability in laboratories. Added to this is the expense of necessary
ancillary resources including complex bioinformatics systems, data processing/analysing and data
storage capabilities. Using targeted sequencing of genes rather than whole genome sequencing can go
some of the way towards reducing the cost of testing [40,41]. In addition, NGS does not afford direct
visualisation of the tested tissue, unlike IHC or RNA in situ hybridisation. Therefore, the presence
or absence of intratumoral heterogeneity, as recently demonstrated in NSCLC [8,39], cannot be easily
determined using NGS, but when there is sufficient coverage, NGS can, to some extent, identify or
suggest the presence of intra tumoral heterogeneity by evaluation of the variant allele frequency (VAF).
More recently, RISH has proven to be effective in detecting the METex14 skipping mutation [23].
The BaseScope® VS Reagent Kit (Red) assay used in our study is an RNA in situ hybridisation assay
based on patented signal amplification and background suppression technology. The assay uses
a proprietary method of in situ hybridisation (ISH) to visualize single RNA molecules per cell in
formalin-fixed paraffin-embedded tissue on mounted slides. This assay does not require the RNA-free
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environment that is required for traditional ISH. The advantage of this technology is that it uses a
fast red dye which offers a high contrast between positive signals and the background tissue, making
analysis of slides by light microscopy more straightforward and efficient. This is of added benefit
where a low copy target gene expression is anticipated (1–20 copies per cell), where the red dot signals
are clearly apparent against background hematoxylin staining. Given that recent studies have shown
the intratumoral heterogeneity of the METex14 mutation [8,39], RISH represents a suitable technology
for the detection of intratumoral heterogeneity within tissue samples.
5. Conclusions
Our results demonstrate the optimization of a PCR methodology to robustly detect METex14
mutated patients in FFPE material by a PCR-based assay, with results comparable to those of similar
studies. This methodology is reliable, efficient, cost-effective and can be utilised by any standard
hospital diagnostic laboratory without the need for any specialized technology such as NGS, RISH
or FISH. Given the recent demonstration of intra-tumoral heterogeneity of METex14 status and the
lack of suitable antibodies to specifically detect METex14 [8,39], RISH may therefore be suitable for
subsequent downstream studies with respect to heterogeneity.
NGS is the current gold standard for identifying METex14, and additionally allows for detection
of numerous alterations needed in NSCLC management, and NGS will, in the future, probably be
routine for all patients presenting with NSCLC. At present, at least in our institute, the cost for NGS
is currently of the order of €400 per patient. Moreover, many hospitals will not have the capacity or
resources to conduct NGS, and often, NGS is requested on a case by case basis. We believe that that
incorporating a pre-screening step using a simple PCR based assay that can be conducted in most
routine hospital laboratories could allow for a cost-effective approach to perhaps pre-screen patients
that may respond to MET inhibitors without the need for conducting NGS, or until all patients can
have NGS conducted as a routine practice.
Our results suggest that, at least for large scale translational studies, a suitable, cost-effective
strategy to screen patients for METEx14 skipping would be via an initial end-point PCR on
formalin-fixed paraffin embedded tissue, followed by NGS to confirm diagnosis in those cases testing
positive by PCR. Subsequently the issue of intratumoral heterogeneity could be assessed using VAF
analysis of NGS data, or RISH could be employed. Finally, our results demonstrate good correlation
between all three testing options/modalities (PCR, NGS and RISH).
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